Q1 Earnings Estimate for ANIP Issued By HC Wainwright

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for ANI Pharmaceuticals in a note issued to investors on Monday, March 3rd. HC Wainwright analyst O. Livnat forecasts that the specialty pharmaceutical company will earn $1.13 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $94.00 target price on the stock. The consensus estimate for ANI Pharmaceuticals’ current full-year earnings is $3.86 per share. HC Wainwright also issued estimates for ANI Pharmaceuticals’ Q2 2025 earnings at $1.31 EPS, Q3 2025 earnings at $1.13 EPS, Q4 2025 earnings at $1.53 EPS, FY2025 earnings at $5.10 EPS and FY2026 earnings at $5.81 EPS.

Several other equities analysts have also issued reports on the company. StockNews.com lowered ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. Leerink Partners began coverage on ANI Pharmaceuticals in a report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 target price for the company. Finally, Guggenheim upped their target price on ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $79.00.

ANI Pharmaceuticals Stock Performance

Shares of ANI Pharmaceuticals stock opened at $61.05 on Thursday. The company has a market cap of $1.28 billion, a PE ratio of -111.00 and a beta of 0.74. ANI Pharmaceuticals has a 52 week low of $52.50 and a 52 week high of $70.81. The business has a 50 day moving average price of $57.53 and a 200-day moving average price of $58.11. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,500 shares of the stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total transaction of $418,425.00. Following the completion of the transaction, the chief financial officer now directly owns 154,468 shares of the company’s stock, valued at approximately $8,617,769.72. This represents a 4.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction on Friday, February 21st. The shares were sold at an average price of $60.20, for a total value of $60,200.00. Following the transaction, the senior vice president now directly owns 68,624 shares of the company’s stock, valued at approximately $4,131,164.80. This trade represents a 1.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 10,300 shares of company stock valued at $584,009. Company insiders own 12.70% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of ANIP. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of ANI Pharmaceuticals by 41.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 47,899 shares of the specialty pharmaceutical company’s stock worth $2,648,000 after acquiring an additional 13,948 shares during the period. Stonepine Capital Management LLC bought a new position in shares of ANI Pharmaceuticals in the fourth quarter worth $1,128,000. Rafferty Asset Management LLC bought a new position in shares of ANI Pharmaceuticals in the fourth quarter worth $200,000. ProShare Advisors LLC boosted its holdings in shares of ANI Pharmaceuticals by 29.0% in the fourth quarter. ProShare Advisors LLC now owns 6,532 shares of the specialty pharmaceutical company’s stock worth $361,000 after acquiring an additional 1,469 shares during the period. Finally, Nomura Holdings Inc. boosted its holdings in shares of ANI Pharmaceuticals by 1.5% in the fourth quarter. Nomura Holdings Inc. now owns 213,879 shares of the specialty pharmaceutical company’s stock worth $11,823,000 after acquiring an additional 3,255 shares during the period. 76.05% of the stock is owned by institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.